|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM114122350 |
| 003 |
DE-627 |
| 005 |
20250202191022.0 |
| 007 |
tu |
| 008 |
231222s2001 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0381.xml
|
| 035 |
|
|
|a (DE-627)NLM114122350
|
| 035 |
|
|
|a (NLM)11513541
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Sporici, R A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a ICOS ligand costimulation is required for T-cell encephalitogenicity
|
| 264 |
|
1 |
|c 2001
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.09.2001
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a CommentIn: Clin Immunol. 2001 Sep;100(3):261-2. doi: 10.1006/clim.2001.5084. - PMID 11513538
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2001 Academic Press.
|
| 520 |
|
|
|a The interaction of ICOS with its ligand on APC provides a costimulatory signal to previously activated T-cells. In these studies, we blocked the ICOS:ICOS ligand interaction with ICOS-Ig during the in vitro activation of MBP-reactive transgenic CD4(+) T-cells. The presence of ICOS-Ig in these cultures inhibited the ability of the transgenic T-cells to transfer EAE, although they entered the brains of the recipient mice. ICOS-Ig increased apoptosis in the transgenic T-cells, especially in the memory population. This enhanced apoptosis was accompanied by an increase in the BAX/BCL-2 mRNA ratio. ICOS-Ig did not prevent IL2 production, demonstrating that IL-2 production is ICOS ligand independent. IFN-gamma and IL-10 production by the transgenic T-cells, however, was suppressed. Finally, ICOS-Ig injection into mice after the first signs of EAE ameliorated clinical disease. Therefore, ICOSL provides a signal distinct from CD28 costimulation that is required for the activation and viability of encephalitogenic T-cells
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Antigens, Differentiation, T-Lymphocyte
|2 NLM
|
| 650 |
|
7 |
|a CD28 Antigens
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Icos protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Inducible T-Cell Co-Stimulator Protein
|2 NLM
|
| 650 |
|
7 |
|a Ligands
|2 NLM
|
| 650 |
|
7 |
|a Proto-Oncogene Proteins c-bcl-2
|2 NLM
|
| 700 |
1 |
|
|a Beswick, R L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a von Allmen, C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rumbley, C A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hayden-Ledbetter, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ledbetter, J A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Perrin, P J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 100(2001), 3 vom: 01. Sept., Seite 277-88
|w (DE-627)NLM098196855
|x 1521-6616
|7 nnns
|
| 773 |
1 |
8 |
|g volume:100
|g year:2001
|g number:3
|g day:01
|g month:09
|g pages:277-88
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 100
|j 2001
|e 3
|b 01
|c 09
|h 277-88
|